$3.20
+0.00 (+0.00%)
Open$3.17
Previous Close$3.20
Day High$3.24
Day Low$3.10
52W High$5.46
52W Low$2.32
Volume—
Avg Volume219.3K
Market Cap117.38M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+374.4% upside
Current
$3.20
$3.20
Target
$15.18
$15.18
$12.50
$15.18 avg
$18.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.06M | 11.02M | 11.79M |
| Net Income | 2.28M | 2.12M | 2.45M |
| Profit Margin | 18.9% | 19.3% | 20.8% |
| EBITDA | 3.37M | 3.22M | 3.75M |
| Free Cash Flow | 1.70M | 2.02M | 1.47M |
| Rev Growth | +16.3% | -0.5% | +13.7% |
| Debt/Equity | 1.56 | 1.35 | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |